Prime Medicine (NASDAQ: PRME) is a publicly traded Gene & Genome Editing Platforms company founded in 2019 and based in Cambridge, United States.
| Date | Stage | Amount | Valuation | Lead investors |
|---|---|---|---|---|
| Oct 20, 2022 | IPO | $175M | — | — |
Prime Medicine reported a net loss of $39.0 million for the quarter ended September 30, 2026, versus $50.6 million a year earlier. Total revenue was $4.2 million, compared with $1.2 million in the prior-year quarter; the release attributes the revenue to collaboration revenue from a related party. Operating expenses fell to $44.1 million from $55.2 million, with R&D at $34.1 million (vs. $44.0 million), which the company attributes to lower restricted stock unit issuance and reduced lab equipment repair facility costs, and G&A at $10.0 million (vs. $11.2 million), driven by lower corporate legal fees. Operationally, the company dosed the first patient in its global Phase 1/2 trial of PM577a for Wilson disease, received FDA IND clearance for PM647 in Alpha-1 Antitrypsin Deficiency, and plans a BLA submission for PM359 in the first half of 2027. It closed an underwritten public offering with $143.7 million gross proceeds (about $134.7 million net). Cash, cash equivalents, investments and restricted cash were $74.8 million at September 30, 2026, versus $191.4 million at December 31, 2025. The company expects cash through 2027, including net offering proceeds, to fund operating expenses and capital expenditures. Initial clinical data for PM577a and PM647 are expected in 2027.
Cash, equivalents and investments as of Sept 30, 2026, plus ~$134.7M net offering proceeds, expected to fund operating expenses and capex through 2027

Prime Medicine has recently raised fresh capital, with analysis questioning how it will deploy the funds.
Prime Medicine updates its corporate presentation on its gene-editing platform.

STAT's biotech newsletter covers a range of trial and deal news, including gene therapy cancer risk and a skeptical take on AI drug discovery.

Gene editing stocks rise after ESGCT conference data and FDA draft guidance, per a StockWatch roundup.

Prime editing is reported to rewrite DNA inside the human body for the first time, per SingularityHub.
Prime editing uses an engineered fusion of a nicking CRISPR protein and a reverse transcriptase, guided by a prime editing guide RNA (pegRNA) that both specifies the target site and carries the new genetic sequence to write. It nicks only one DNA strand and copies in the edit directly, so it needs no double-strand break and no separate donor template. The approach can install all twelve single-base substitutions plus small insertions and deletions, giving a single platform the breadth to correct the majority of known disease-causing mutations.
We don't have a live feed for this company's ATS. Their careers page has every open role.
View all careers ↗